Dr. Eggermont on the Impact of Adjuvant Anti-PD-L1 Agents in Melanoma
April 18th 2018Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of adjuvant anti–PD-L1 agents on the treatment landscape of melanoma.
Read More